Beam Therapeutics (BEAM) Return on Equity (2019 - 2025)
Beam Therapeutics (BEAM) has disclosed Return on Equity for 7 consecutive years, with 0.07% as the latest value for Q4 2025.
- Quarterly Return on Equity rose 41.0% to 0.07% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.07% through Dec 2025, up 41.0% year-over-year, with the annual reading at 0.08% for FY2025, 36.0% up from the prior year.
- Return on Equity for Q4 2025 was 0.07% at Beam Therapeutics, up from 0.41% in the prior quarter.
- The five-year high for Return on Equity was 0.07% in Q4 2025, with the low at 0.91% in Q1 2021.
- Average Return on Equity over 5 years is 0.37%, with a median of 0.38% recorded in 2022.
- The sharpest move saw Return on Equity skyrocketed 201bps in 2021, then tumbled -34bps in 2024.
- Over 5 years, Return on Equity stood at 0.42% in 2021, then grew by 8bps to 0.38% in 2022, then surged by 63bps to 0.14% in 2023, then plummeted by -242bps to 0.49% in 2024, then soared by 85bps to 0.07% in 2025.
- According to Business Quant data, Return on Equity over the past three periods came in at 0.07%, 0.41%, and 0.37% for Q4 2025, Q3 2025, and Q2 2025 respectively.